73 related articles for article (PubMed ID: 22289920)
1. Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Ralli R; Banks KM; Wiegmans AP; Carney D; Seymour JF; Johnstone RW; Alsop AE
Leukemia; 2012 Jun; 26(6):1433-5. PubMed ID: 22289920
[No Abstract] [Full Text] [Related]
2. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
3. ABT-737, proving to be a great tool even before it is proven in the clinic.
Vaux DL
Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
[No Abstract] [Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Bruno S; Ghiotto F; Tenca C; Mazzarello AN; Bono M; Luzzi P; Casciaro S; Recchia A; Decensi A; Morabito F; Fais F
Leukemia; 2012 Oct; 26(10):2260-8. PubMed ID: 22475870
[TBL] [Abstract][Full Text] [Related]
5. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
[TBL] [Abstract][Full Text] [Related]
6. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
Soderquist R; Bates DJ; Danilov AV; Eastman A
Leukemia; 2013 Nov; 27(11):2262-4. PubMed ID: 23640104
[No Abstract] [Full Text] [Related]
7. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
10. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
11. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
12. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
[TBL] [Abstract][Full Text] [Related]
13. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
[TBL] [Abstract][Full Text] [Related]
14. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
[TBL] [Abstract][Full Text] [Related]
15. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
16. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
[No Abstract] [Full Text] [Related]
17. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
Singh A; Jayanthan A; Farran A; Elwi AN; Kim SW; Farran P; Narendran A
Leuk Res; 2011 Dec; 35(12):1649-57. PubMed ID: 21798596
[TBL] [Abstract][Full Text] [Related]
18. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
19. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
Whitecross KF; Alsop AE; Cluse LA; Wiegmans A; Banks KM; Coomans C; Peart MJ; Newbold A; Lindemann RK; Johnstone RW
Blood; 2009 Feb; 113(9):1982-91. PubMed ID: 19060243
[TBL] [Abstract][Full Text] [Related]
20. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
